20/10/2026
Appendicectomy plus standard medical therapy versus standard medical therapy alone for maintenance of remission in ulcerative colitis (ACCURE): a pragmatic, open-label, international, randomised trial
The ACCURE Study Group, Lancet Gastroenterol Hepatol 2025; 10: 550–61
20/10/2026
Impact of diet on inflammatory bowel disease risk: systematic review, meta-analyses and implications for prevention
Antoine Meyer, a,b,c,i Manasi Agrawal, d,e,f,i Einat Savin-Shalom, d Emily C. L. Wong, g Carrie Levinson, h Stephanie Gold, d Neeraj Narula, g Jean-Frédéric Colombel, d,j and Franck Carbonnel
03/08/2024
Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus
Pablo A. Olivera, Laurent Peyrin-Biroulet et al. DLD 2024
20/08/2023
Management of inflammatory bowel disease in the elderly: A review
DLD Digestive and Liver Disease 55 (2023) 1001–1009
18/07/2023
Mirikizumab as Induction and Maintenance Therapy for Ulcerative Colitis
NEJM
04/06/2023
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
NEJM - E.V. Loftus, Jr., J. Panes, A.P. Lacerda, L. Peyrin‑Biroulet, G. D’Haens, R. Panaccione, W. Reinisch, E. Louis, M. Chen, H. Nakase, J. Begun, B.S. Boland, C. Phillips, M.-E.F. Mohamed, J. Liu, Z. Geng, T. Feng, E. Dubcenco, and J.-F. Colombel
31/05/2023
Use of biologics for the management of Crohn’s disease: IG-IBD technical review based on the GRADE methodology
Digestive and Liver Disease: June 2023 (Volume 55, Issue 6)
31/05/2023
Prevention of post-operative recurrence of Crohn’s disease among patients with prior anti-TNF αfailure: A retrospective multicenter study
Digestive and Liver Disease: June 2023 (Volume 55, Issue 6)
28/04/2023
Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis
Digestive and Liver Disease 55 (2023) 580–586
10/03/2023
Mucosal healing with vedolizumab in inflammatory bowel disease patients with chronic pouchitis: Evidence from EARNEST, a randomized, double-blind, placebo-controlled trial
OP08 at ECCO 18th - Jairath, V.; Feagan, B.G.; Danese, S.; Gionchetti, P.; Travis, S.
28/01/2023
Ustekinumab and vedolizumab for the prevention of postoperative recurrence of Crohn’s disease: Results from the ENEIDA registry
ENEIDA registry by GETECCU
04/12/2022
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors
Onali S, et al. Am J Gastroenterol . 2022 Aug 1;117(8):1279-1287.
12/10/2022
Superior Effectiveness of Tofacitinib Compared to Vedolizumab in Anti-TNF-experienced Ulcerative Colitis Patients: A Nationwide Dutch Registry Study
Clinical Gastroenterology and Hepatology 2022
27/09/2022
Mistakes in the management of postoperative Crohn’s disease and how to avoid them
UEG education - Eugeni Domènech and Míriam Mañosa
07/08/2022
Segmental Versus Total Colectomy for Crohn’s Disease in the Biologic Era: Results From The SCOTCH International, Multicentric Study
Pellino G, Rottoli M, Mineccia M, Frontali A, Celentano V, Colombo F, Baldi C, Ardizzone S, Poggioli G, Sampietro GM, et al. JCC 2022
21/07/2022
Comparative Efficacy for Infliximab Vs Vedolizumab in Biologic Naive Ulcerative Colitis
CGH 2022
20/07/2022
International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases
UEG Journal
11/06/2022
COVID-19 Vaccine Is Effective in Inflammatory Bowel Disease Patients and Is Not Associated With Disease Exacerbation
Clinical Gastroenterology and Hepatology, June 2022
13/04/2022
PICaSSO virtual electronic chromendoscopy accurately reflects combined endoscopic and histological assessment for prediction of clinical outcomes in ulcerative colitis.
UEG Journal
08/03/2022
Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial
William J. Sandborn, Bruce E. Sands, Stephen B. Hanauer, Subrata Ghosh, Jean-Frederic Colombel,j Brian G. Feagan, and John P. Lynch CGH2022
15/02/2022
Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives
Authors: Peter M Irving, Krisztina B Gecse - Gastroenterology February 2022
05/01/2022
Upadacitinib Was Efficacious and Well Tolerated Over 30 Months in Patients with Crohn’s Disease in the CELEST Extension Study
Clinical Gastroenterology and Hepatology - Geert D’Haens, Julian Panés, Edouard Louis, Ana Lacerda, Qian Zhou, John Liu,Edward V. Loftus, Jr.
30/12/2021
COVID-19 vaccine is effective in inflammatory bowel disease patients and is not associated with disease exacerbation
Clinical Gastroenterology and Hepatology 12.2021
04/11/2021
Mistakes in colonoscopic surveillance in IBD and how to avoid them
UEG Education, 2021 - Matthew D Rutter
01/10/2021
Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis.
William J. Sandborn et al., NEJM September 30th, 2021
28/08/2021
Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial
Séverine Vermeire, William J Sandborn et al. Journal of Crohn's and Colitis, 17 August 2021
04/08/2021
Comparative Efficacy for Infliximab vs. Vedolizumab in Biologic Naive Ulcerative Colitis
Neeraj Narula, MD, MPH, FRCPC, Jean-Frederic Colombel, MD, Walter Reinisch, MD, PhD Published CGH July 27, 2021 DOI:https://doi.org/10.1016/j.cgh.2021.07.038
03/07/2021
Long-Term Safety and Efficacy of Risankizumab Treatment in Patients with Crohn’s Disease: Results from the Phase 2 Open-Label Extension Study
Journal of Crohn's and Colitis, 02 June 2021 Marc Ferrante, Brian G Feagan, et al.
05/06/2021
Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn’s Disease in Endoscopic Remission.
Clinical Gastroenterology and Hepatology June_2021 - Anne B. Hu, William Tan,Vikram Deshpande, and Ashwin N. Ananthakrishnan.
11/05/2021
STRIDE II An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
Gastroenterology, 04/2021
04/04/2021
Ultrasonography tight control and monitoring in Crohn’s disease during different biological therapies: a multicenter study
E. Calabrese, A. Rispo, F. Zorzi, E. De Cristofaro, A. Testa, G. Costantino, A. Viola, C. Bezzio, C. Ricci, S. Prencipe, C. Racchini, G. Stefanelli, M. Allocca, M. Cappello, G. Maconi, A. Spagnoli, G. Monteleone, F. Castiglione et al
03/03/2021
Five-year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: the IM-UNITI trial
Sandborn WJ, Rebuck R, Wang Y, Zou B, Adedokun OJ, Gasink C, Sands BE, Hanauer SB, Targan S, Ghosh S, de Villiers WJ, Colombel J-F, Feagan BG, Lynch JP. Clinical Gastroenterology and Hepatology (2021), doi: https://doi.org/10.1016/j.cgh.2021.02.025.
17/02/2021
Ustekinumab for Ulcerative colitis
Reena Khanna, MD, Waqqas Afif, MD. Gastroenterology (2021) https://doi.org/10.1053/j.gastro.2021.02.002.
28/01/2021
Incidence of and risk factors for colorectal strictures in ulcerative colitis: a multicenter study
Pierre-Antoine Laurain ∗ Laurent Peyrin-Biroulet. Clinical Gastroenterology and Hepatology January 21, 2021 - DOI: https://doi.org/10.1016/j.cgh.2021.01.028
26/10/2020
Incremental Benefit of Achieving Endoscopic and Histologic Remission in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis
Gastroenterology, June 2020
09/04/2020
Efficacia nella vita reale di Tofacitinib in pazienti con colite ulcerosa refrattaria
Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis Lair-Mehiri L, Digestive and Liver Disease, 2020-03-01,52 (3) 268-273
16/01/2020
Vedolizumab versus Adalimumab nel trattamento della colite ulcerosa moderato-severa – studio VARSITY
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis Sands BE et al. N.Engl J Med 2019;381:1215-26
25/11/2019
Ustekinumab come terapia di induzione e mantenimento in pazienti affetti da rettocolite ulcerosa - studio UNIFI
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. Sands BE et al. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750
21/04/2019
Monitoraggio dei livelli terapeutici di farmaci biologici ed anticorpi anti farmaco in pazienti con malattie infiammatorie croniche intestinali
Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases. Papamichael K et al. Clin Gastroenterol Hepatol. 2019 Mar 27
20/01/2019
Efficacia del trapianto fecale sulla remissione a 8 settimane in paziente affetti da rettocolite ulcerosa
Effect of Fecal Microbiota Transplantation on 8-Week Remission in Patients With Ulcerative Colitis: A Randomized Clinical Trial. Costello SP et al. JAMA. 2019 Jan 15;321(2):156-164
08/06/2018
Ripetute colonscopie di sorveglianza negative sono predittive di un basso rischio di CCR in pazienti con colite long-standing
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis
05/05/2018
Rischio di infezioni severe ed opportunistiche in corso di trattamento per malattie infiammatorie intestinali
Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel Diseases. Kirchgesner J et al. Gastroenterology. 2018 Apr 12. [Epub ahead of print]
24/04/2018
Lo switch ad Infliximab biosimilare è sicuro e ben tollerato in pazienti con IBD in remissione (studio SECURE)
Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trialStrik AS et al.
12/01/2018
Morgensen (GED-0301) è efficace sugli outcome sia clinici che endoscopici a 12 settimane in pazienti con malattia di Crohn in fase attiva
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.Feagan BG et al. Gastroenterology. 2018 Jan;154(1):61-64
30/12/2017
La colonscopia con endoscopi ad alta definizione è sovrapponibile alla cromoendoscopia nella sorveglianza delle coliti long standing
A Randomized Trial Comparing High Definition Colonoscopy Alone With High Definition Dye Spraying and Electronic Virtual Chromoendoscopy for Detection of Colonic Neoplastic Lesions During IBD Surveillance Colonoscopy. Iacucci M et al. Am J Gastroenterol. 2017 Nov 14. [Epub ahead of print]
15/11/2017
Indicatori di risposta sub-ottimale a terapia con anti-TNF nelle IBD
Indicators of suboptimal tumor necrosis factor antagonist therapy in inflammatory bowel disease. Lindsay JO, Armuzzi A, Gisbert JP et al. Dig Liver Dis. 2017 Oct;49(10):1086-1091
28/08/2017
Efficacia e sicurezza di anticorpi anti MAdCAM nel trattamento della colite ulcerosa: lo studio TURANDOT
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.Vermeire S et al. Lancet. 2017 Jul 8;390(10090):135-144. doi: 10.1016/S0140-6736(17)30930-3. Epub 2017 May 17.
20/07/2017
I livelli sierici di Infliximab all'induzione sono predittivi della risposta o del fallimento della terapia durante il mantenimento
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance. Liefferinckx C et al. Inflamm Bowel Dis. 2017 Aug;23(8):1371-1381
07/05/2017
MEDI2070, anticorpo monoclonale anti-IL23 efficace nella malattia di Crohn moderato-severa
Sands BE et al. Efficacy and Safety of MEDI2070, an antibody against interleukin 23, patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology. 2017 Apr 5. [Epub ahead of print]
07/04/2017
Efficacia del trapianto fecale da donatori multipli nella colite ulcerosa in fase di attività
Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Paramsothy S et al. Lancet. 2017 Mar 25;389(10075):1218-1228. doi: 10.1016/S0140-6736(17)30182-4.
06/02/2017
Remissione clinica in pazienti con malattia di Crohn moderato-severa trattati con Filgotinib
Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet 2017 Jan 21;389(10066):266-275.
01/01/2017
La sorveglianza endoscopica con biopsie mirate identifica un tasso simile di neoplasia rispetto alle biopsie random nei pazienti con RCU long-standing
Comparison of Targeted vs Random Biopsies for Surveillance of Ulcerative Colitis-Associated Colorectal Cancer. Watanabe T et al. Gastroenterology. 2016 Dec;151(6):1122-1130.
21/02/2013
Flora intestinale ed IBD: un'altra prospettiva
V.Annese Scrive
21/02/2013
L'FDA ha approvato Remicade per il trattamento della colite ulcerosa
L’FDA ha approvato Remicade ( Infliximab ) nel trattamento della colite ulcerosa, forma moderata-severa. L’approvazione è avvenuta grazie ai risultati degli studi clinici ACT1 e ACT2.
21/02/2013
RCU: l'endoscopia aiuta a predire il rischio di cancro!!!
Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk . M D Rutter, B P Saunders, K H Wilkinson, S Rumbles, G Schofield, M A Kamm, C B Williams, A B Price, I C Talbot, A Forbes. Gut 2004;53:1813-1816
15/04/2009
Una adeguata informazione del paziente è indispensabile per migliorare la aderenza alle terapie
Qualitative Investigation of Patient Adherence to 5-Aminosalicylic Acid Therapy in Patients with Ulcerative Colitis
15/04/2009
E' possibile il mantenimento con mesalazina in monsomministrazione nei pazienti con colite ulcerosa in remissione
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
15/04/2009
Nei pazienti con colite ulcerosa in fase attiva la terapia con mesalazina orale puo' essere prescritta in signola dose giornaliera
Once daily versus three times daily mesalazine granules in active ulcerative
15/04/2009
Mesalazina orale nei pazienti con colite ulcerosa attiva: possono essere utili terapie prolungate nei pazienti con scarsa risposta?
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative
15/04/2009
Mesalazina nella chemioprevenzione del carcinoma coloretttale: ancora qualche dato controverso
Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
15/04/2009
Una nuova terapia per la colite ulcerosa refrattaria alla mesalazina: il desametasone veicolato dagli eritrociti
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate
15/04/2009
Colite ulcerosa grave stroido-dipendente: sono da evitare terapie di terza linea
Cyclosporine and infliximab as rescue therapy for each other in patients with
15/04/2009
L'azatioprina riduce le recidive endoscopiche post-chirurgiche nei pazienti con malattia di Crohn ad alto rischio di recidiva
Therapy of metronidazole with azathioprine to prevent postoperative recurrence of
15/04/2009
Mantenimento con infliximab nella colite ulcerosa steroido-refrattaria: i primi dati sul campo
Experience of maintenance infliximab therapy for refractory ulcerative colitis
15/04/2009
Confermata l'utilità della mercaptopurina nei pazienti con intolleranza all'azatioprina di tipo idiosincrasico
Mercaptopurine treatment should be considered in azathioprine intolerant patients
15/04/2009
Il cotrattamento con mesalazina nei pazienti in terapia immunosoppressoria non ha alcun vantaggio dimostrato
Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes?
30/09/2008
Consensus ECCO su diagnosi e trattamento della colite ulcerosa (Berlino , 20 ottobre 2006) - Definizioni e diagnosi
European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis
30/09/2008
Consensus ECCO su diagnosi e terapia della colite ulcerosa (Berlino , 20 ottobre 2006) - Current Management
European evidence-based Consensus on the management of ulcerative colitis: Current management
30/09/2008
Consensus ECCO su diagnosi e terapia della colite ulcerosa (Berlino , 20 ottobre 2006) - Special Situations
European evidence-based Consensus on the management of ulcerative colitis: Special situations
22/09/2007
Certolizumab nel trattamento del Crohn: i risultati del PRECISE study
Certolizumab pegol for the treatment of Crohn's disease.Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S; PRECISE 1 Study Investigators. N Engl J Med. 2007 Jul 19;357(3):228-38.
02/09/2006
Efficacia della terapia steroidea nelle IBD: uno studio di coorte
The efficacy of corticosteroid therapy in inflammatory bowel disease:analysis of a 5-year UKinception cohort. Ho GT,Chiam P, Drummond H, Loane J, Arnott ID, Satsangi J.CHAR(13) + CHAR(10) Aliment Pharmacol Ther. 2006 Jul15;24(2):319-30.
03/07/2006
La videocapsula è la migliore tecnica diagnostica per il Crohn del tenue
20/06/2006
Fattori prognostici e protettivi di cancro nella Colite Ulcerosa
lbenazzato Scrive"Predictive and protective factors associated with colorectal cancer inCHAR(13) + CHAR(10)ulcerative colitis: a case-control study.CHAR(13) + CHAR(10)CHAR(13) + CHAR(10)Velayos FS, Loftus EV Jr, Jess T, Harmsen WS, Bida J, Zinsmeister AR, TremaineCHAR(13) + CHAR(10)WJ, Sandborn WJ.CHAR(13) + CHAR(10)Gastroenterology. 2006 Jun;130(7):1941-9.CHAR(13) + CHAR(10)
18/06/2006
Colite ulcerosa : quale mesalazina?
Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
Gibson PR, Fixa B, Pekarkova B, Batovsky M, Radford-Smith G, Tibitanzl J, Gabalec L, Florin TH, Greinwald R.
Aliment Pharmacol Ther. 2006 Apr 1;23(7):1017-26.
08/06/2006
Anti-TNF e rischio linfoma : una meta-analisi.....
28/05/2006
DDW 2006: efficacia e sicurezza dell'Adalimumab nella terapia del Crohn
Adalimumab Induces and Maintains Clinical Response and Remission in Patients With Active Crohn’s Disease: Results of the CHARM Trial
J. Colombel; W. J. Sandborn; P. Rutgeerts; R. Enns; S. B. Hanauer; P. Remo; S. Schreiber; K. G. Lomax; P. F. Pollack
22/05/2006
I livelli dei metaboliti predicono la tossicità da tiopurine nelle IBD
19/05/2006
Lo stress non è un trigger per il relapse delle IBD
23/04/2006
Una nuova terapia per il Crohn?
18/04/2006
La prognosi del K colon in pazienti con IBD.......
14/04/2006
RCU Atto 1° e 2°: L'ora dell'Infliximab.
07/04/2006
Infliximab e rischio di neoplasia: uno studio multicentrico.......
Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study.
Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benazzato L, Papi C, Meucci G, Riegler G, Petruzziello C, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F.
Gut. 2006 Feb;55(2):228-33. Epub 2005 Aug 24.
30/03/2006
Il fontolizumab (anti-interferon-gamma) nella terapia del Crohn
28/03/2006
USO DI STEROIDI, IMMUNOMODULATORI E INFLIXIMAB NELLE IBD
25/03/2006
I coxibs sono sicuri nella RCU.......
24/03/2006
E' possibile reintrodurre l'azatioprina in soggetti intolleranti?
Re-introduction of azathioprine in previously intolerant patients.
Green CJ, Mee AS.
Eur J Gastroenterol Hepatol. 2006 Jan;18(1):17-9
13/03/2006
Infliximab + metotrexate nella malattia di Crohn refrattaria
12/03/2006
Azatioprina vs 5-ASA nel trattamento della colite ulcerosa: un RCT !
14/02/2006
C'è un ruolo per il Natalizumab nella terapia del Crohn?
Natalizumab induction and maintenance therapy for Crohn's disease.
Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P; International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group.
N Engl J Med. 2005 Nov 3;353(18):1912-25.
13/02/2006
Trombofilia e IBD: una review….
Inflammation andCoagulation in Inflammatory Bowel Disease: The Clot Thickens.Danese S, Papa A, Saibeni S, Repici A, Malesci A,Vecchi M.Am J Gastroenterol.2006 Nov 13; [Epub ahead of print]
13/02/2006
Trombofilia e IBD: una review….
Inflammation andCoagulation in Inflammatory Bowel Disease: The Clot Thickens.Danese S, Papa A, Saibeni S, Repici A, Malesci A,Vecchi M.Am J Gastroenterol.2006 Nov 13; [Epub ahead of print]
12/02/2006
Crohn e rischio di cancro: una meta-analisi di studi osservazionali!
10/02/2006
Management della RCU sinistra e della proctite
Guidelines for the Medical Management of Left-Sided Ulcerative Colitisand Ulcerative Proctitis: Summary Statement.CHAR(13) + CHAR(10)Regueiro M, Loftus EV Jr, SteinhartAH, Cohen RD.CHAR(13) + CHAR(10)Inflamm Bowel Dis. 2006 Oct;12(10):972-978.
10/02/2006
Management della RCU sinistra e della proctite
Guidelines for the Medical Management of Left-Sided Ulcerative Colitisand Ulcerative Proctitis: Summary Statement.CHAR(13) + CHAR(10)Regueiro M, Loftus EV Jr, SteinhartAH, Cohen RD.CHAR(13) + CHAR(10)Inflamm Bowel Dis. 2006 Oct;12(10):972-978.
09/02/2006
RCU: la mesalazina MMX è sicura ed efficace
Once daily MMX mesalazine for the treatment ofmild-to-moderate ulcerative colitis: a phase II, dose-ranging study.D'Haens G, Hommes D, Engels L, Baert F, VAN DER WaaijL, Connor P, Ramage J, Dewit O, Palmen M, Stephenson D, Joseph R. AlimentPharmacol Ther. 2006 Oct 1;24(7):1087-97.
07/02/2006
Review sulle IBD
27/01/2006
Tacrolimus nelle IBD ... una review
The Role of Tacrolimus in Inflammatory Bowel Disease: A SystematicReview.Gonzalez-Lama Y, Gisbert JP, Mate J.Dig Dis Sci. 2006 Sep 9; [Epubahead of print]
11/01/2006
IBD: infezione da CMV un riscontro frequente....
Frequent Detection of Cytomegalovirus in the Intestine of Patients withInflammatory Bowel Disease.Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Inflamm Bowel Dis. 2006 Sep;12(9):879-884.
08/01/2006
Azatioprina e rischio di linfoma
04/01/2006
Strategie di terapia nel m. di Crohn: step-up o top-down ?
V.Annese Scrive"Management of Recent Onset Crohn’s Disease: A Controlled, Randomized Trial Comparing Step-up and Top-down TherapyCHAR(13) + CHAR(10)Hommes D, Baert F, van Assche G, Caenepeel F, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Rutgeerts P, Feagan B, D’Haens GGastroenterology 2005,129:371CHAR(13) + CHAR(10)